Overview

This trial is active, not recruiting.

Condition breast cancer risk
Phase phase 4
Sponsor University of Wisconsin, Madison
Collaborator Department of Defense
Start date July 2008
End date February 2010
Trial size 270 participants
Trial identifier NCT00839696, CC07104

Summary

Mammographic density is sensitive to estorgen exposure and constitutes a strong intermediate maker of breast cancer risk. We hypothesize that women with higher serum xenoestrogen levels will have greater mammographic density.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Measure
Characterize the distribution of total xenoestrogen burden and identify important source of xenoestrogen exposure among a clinic-based sample of postmenopausal women.
time frame: 1 year

Secondary Outcomes

Measure
Evaluate the association of total xenoestorgen exposure with mammographic density.
time frame: 1 year

Eligibility Criteria

Female participants from 55 years up to 70 years old.

Inclusion Criteria: - 55-70 years of age, Post menopausal Exclusion Criteria: - If they have ever used hormone replacment therapy or have ever used Tamoxifen or Raloxifene, Diag. with breast cancer have had breast implants or have had a mastectomy/

Additional Information

Official title Total Xonoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Risk
Principal investigator Amy Trentham Dietz, PhD
Trial information was received from ClinicalTrials.gov and was last updated in November 2011.
Information provided to ClinicalTrials.gov by University of Wisconsin, Madison.